Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > The Bracelet-1 90 day exclusivity should be over x Feb 2023

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Nov 21, 2022 12:38pm

125 Views

Post# 35115773

RE:RE:The Bracelet-1 90 day exclusivity should be over x Feb 2023

As most already know James T. Parsons negotiated the acquisition of the pre-clinical company Trillium Therapeutics by Pfizer for US$2.3 Billion.

In contrast ONCY is a late clinical stage company with a platform technology in pelareorep that can be used in multiple cancers in combination with multiple immuno-oncology agents like immune checkpoint inhibitor, CAR-T anti-body therapy, bispecifics, and small molecule I/O agents.

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023